About Angelini Ventures
Angelini Ventures is a venture capital firm founded in 2021. It is primarily based out of Rome, Italy. As of Jul 2026, Angelini Ventures is an active investor, having invested in 27 companies, with 5 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and High Tech. Most recently it participated in the $***** Series B round of Handspring Overall, Angelini Ventures portfolio has seen 1 acquisition, namely Noctrix Health. A lot of funds co-invest with Angelini Ventures, with names like Kurma Partners sharing a substantial percentage of its portfolio. Angelini Ventures has team of 19 people including 8 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 2 more
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Angelini Ventures' List of Top Investments
Angelini Ventures has a portfolio of 27 companies. Their most notable investments are in Therini Bio and Cour Pharma.Their portfolio spans across United States, Italy, France and 9 more locations. They have invested in Life Sciences, HealthTech, High Tech and 4 other sectors, across stages such as Seed, Series A and 2 more. Here is the list of top investments by Angelini Ventures:
1. Nuevocor
Developer of genetic medicines for treating rare heart muscle conditions. These therapies target underlying mechanical defects in heart tissue to address disease progression. The focus remains on creating treatments for specific genetic cardiomyopathies that currently lack effective therapeutic options.
Key facts about Nuevocor
- Founded Year: 2021
- Location: Singapore (Singapore)
- Stage: Series B
- Total Funding till date: $80.6M
- Employee Count: 29 as on Jun 30, 2026
- Investors: EDBI, Boehringer Ingelheim Venture Fund and 7 Others
- Latest Funding Round: Series B, May 06, 2025, $*****
- Highlight: Editors' Pick
AI-based tissue analysis software for surgical precision. The company has developed software that assists clinicians during medical surgery by providing computer-assisted tissue analysis technology. It has features to provide real-time tissue analysis, tissue & surgery measurement, optical imaging, AI-based quantitative imaging, and more.
Key facts about Hypervision Surgical
- Founded Year: 2020
- Location: London (United Kingdom)
- Stage: Series A
- Total Funding till date: $31M
- Employee Count: 28 as on Jun 30, 2026
- Investors: IP Group, Life Extension Ventures and 10 Others
- Latest Funding Round: Series A, Apr 29, 2026, $*****
- Highlight: Editors' Pick
Developer of therapeutics for the treatment of rare diseases. It offers an in-silico platform that enables the design of small molecules that stabilizes misfolded proteins to treat rare diseases. It offers computational drug discovery engine called Revenir which captures the biophysical changes caused by mutations in proteins. It examines surface features and numerous biophysical descriptors of both the mutated and wild-type proteins. It offers a lead candidate CGX-926 for obesity.
Key facts about Congruence Therapeutics
Noctrix Health is engaged in developing prescription-grade wearable therapeutic devices. They are developing a medical device for treating chronic neurological disorders, especially to treat the symptoms of restless leg syndrome.
Key facts about Noctrix Health
- Founded Year: 2016
- Location: San Francisco (United States)
- Stage: Acquired
- Total Funding till date: $90.5M
- Employee Count: 163 as on Jun 30, 2026
- Investors: Sectoral, Orbimed and 15 Others
- Latest Funding Round: Series C, Aug 29, 2025, $*****
- Highlight: Acquired
5. Pretzel
Developer of therapeutics to treat rare genetic disorders and mitochondrial dysfunction. The company uses its proprietary technology to develop therapeutics that can address mitochondrial dysfunction which is associated with a wide range of diseases.
Key facts about Pretzel
- Founded Year: 2018
- Location: Waltham (United States)
- Stage: Series A
- Total Funding till date: $72.5M
- Employee Count: 49 as on Jun 30, 2026
- Investors: Mubadala, Google Ventures and 10 Others
- Latest Funding Round: Series A, Sep 12, 2022, $*****
Angelini Ventures' Year-on-Year Investment Trends
Angelini Ventures has invested in 27 companies over the last 5 years, with an average of 5 new investments annually in the last 5 years. In 2025, it made 11 investments, while as of Jul 2026, it has made 4 investments in this year. Its most recent first time investment was in Handspring and most recent follow-on round was in Nuclidium.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 1 | 4 |
2025 | 9 | 2 | 11 |
2024 | 3 | 1 | 4 |
2023 | 5 | 0 | 5 |
2022 | 3 | 0 | 3 |
2021 | 1 | 0 | 1 |
Angelini Ventures' Investments by Stage
Angelini Ventures has made 8 investments in Seed stage with an average round size of $6.07M, 8 investments in Series A stage with an average round size of $53.9M, 5 investments in Series B stage with an average round size of $45.1M and 3 investments in Series C stage with an average round size of $48M.Stage of entry | No. of Investments |
|---|---|
Seed | 8 |
Series A | 8 |
Series B | 5 |
Series C | 3 |
Note: We have considered here, only first round of investments
Angelini Ventures' Investments by Sector
Angelini Ventures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Consumer, Enterprise Applications and High Tech. Notably, it has invested in 23 Tech companies, 20 Enterprise (B2B) companies, 6 Consumer (B2C) companies and at least 6 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 18 |
HealthTech | 8 |
Consumer | 4 |
Enterprise Applications | 3 |
High Tech | 3 |
Others | 5 |
Note: We have considered here, only first round of investments
Angelini Ventures' Investments by Geography
Angelini Ventures has made most investments in United States (9), followed by Italy where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 9 |
Italy | 3 |
Denmark | 2 |
France | 2 |
Switzerland | 2 |
Others | 8 |
Note: We have considered here, only first round of investments
Angelini Ventures' recent investments
Angelini Ventures has made 4 investments in 2026 so far. Handspring and Ema Health are the latest among them.Here are the most recent investments by Angelini Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jul 07, 2026 | United States | Series B | 5575 | [+5] | |
Jun 10, 2026 | Italy | Seed | 8248 | [+5] | |
May 27, 2026 | Switzerland | Series B | 5776 | [+7] | |
Apr 29, 2026 | United Kingdom | Series A | 5444 | [+7] | |
Dec 04, 2025 | Netherlands | Seed | 3555 | [+7] |
Acquired companies in Angelini Ventures' Portfolio
1 company from Angelini Ventures' portfolio has been acquired. The most recent acquisition was Noctrix Health in Apr 2026 by ResMed for $*****.Here are Angelini Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Jan 16, 2024 | Series C | 7553 |
Team profile of Angelini Ventures
Angelini Ventures has a team of 19 members including 8 Partners, 1 Venture Partner and 4 Principals located in United States, Italy and 5 more locations. Angelini Ventures' team sits on the board of 6 companies.Here is a list of top team members in Angelini Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Munich | SNIPR Biome, STipe Therapeutics and 1 more | ||
Partner | Milan | - | ||
Partner | Singapore | - | ||
Partner | Rome | - | - | |
Partner | New York City | - | - | |
Partner | Hamburg | - | - | |
Partner | Lausanne | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - |
Co-investors of Angelini Ventures
Over the past 5 years, 170 investors have co-invested in Angelini Ventures's portfolio companies. This includes funds and angels.
- Invested before Angelini Ventures: HHS, Life Sciences Partners and 46 others have invested in rounds before Angelini Ventures. There are 2 companies where HHS has invested before Angelini Ventures and 2 companies where Life Sciences Partners has invested before Angelini Ventures.
- Top Co-investors of Angelini Ventures: 98 investors entered a company along with Angelini Ventures. These include investors like Kurma Partners (5 companies).
- Invested after Angelini Ventures: A total of 24 investors have invested in Angelini Ventures's portfolio after their investments. Top Investors include BVF (1 company), Bridge Bank (1 company) and CDP Venture Capital (1 company).
Recent News related to Angelini Ventures
•
•
•
NUCLIDIUM AG Announces Closing of Series B Extension, Raising Total Round to CHF 105 MillionGlobeNewswire•May 27, 2026•Angelini Ventures, Nuclidium, DeepTech & Climate Fonds, Neva SGR and 5 others
•
•
Laigo Bio Raises €11.5M in Seed FinancingFinSMEs•Dec 04, 2025•Laigo Biotechnology, Kurma Partners, Curie Capital, Argobio and 3 others
•
•
European Investment Bank Provides EUR 35 Million Venture Debt Financing to Sidekick HealthGlobal Legal Chronicle•Nov 27, 2025•SidekickHealth, European Investment Bank, Angelini Ventures
•
London’s CoMind Raises €85M To Revolutionize Non-invasive Brain MonitoringStartup Rise EU•Oct 20, 2025•CoMind, GE Healthcare, Angelini Ventures, Plural and 2 others
•
CoMind raises €87.8M to advance AI-powered, non-invasive brain monitoringSilicon Canals•Oct 20, 2025•Phoenix Court, Angelini Ventures, Pluralsight, Government of Kerala and 7 others
•
Adcytherix Raises €105 Million to Advance Antibody-Drug Conjugate PortfolioGlobeNewswire•Oct 16, 2025•Adcytherix, Bpifrance, Angelini Ventures, Citadel and 4 others
